SYRE · Spyre Therapeutics, Inc.
$107.79
-1.13 (-1.04%)
At close · Aug 20
Going-concern doubt
— flagged Aug 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We will need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Market Cap
$9.38B
Shares
88.17M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Key facts
CIK
1636282
CUSIP
00773J202
13F (30d)
256 filings
253 filers
Visit website
Investor relations